Phase 2 Study Of AT9283 Is Initiated For Relapsed/Refractory Myeloma – The NCIC National Clinical Trials Group has initiated a Phase 2 clinical trial studying the developmental drug AT9283 in relapsed and refractory multiple myeloma patients. The trial will take place at several treatment centers in Canada. AT9283, which is being developed by Astex Therapeutics, inhibits cell division and has been shown in pre-clinical studies to stop the growth of multiple myeloma cells. Phase 1 clinical trials have tested AT9283 for safety in patients with a number of blood cancers and solid tumors. For more information, see the Astex press release and the clinical trial description.

Turkey Trots To Benefit The Leukemia & Lymphoma Society – Three Turkey Trots will take place in New York State on Thanksgiving (November 25) to benefit the Leukemia & Lymphoma Society. The Turkey Trots will take place in Garden City, Smithtown, and Massapequa. Participants have the choice between runs of several different distances. For more information, see the event websites.

Myeloma Symposium In Germany – An information session for multiple myeloma patients will be held on November 18 in Freiburg, Germany. There will be several presentations about new developments and therapies in myeloma as well as a question and answer session. The event will be held at the University of Freiburg and will begin at 5 p.m. For more information, see the Myeloma Euronet website (pdf in German).

For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.